Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models

Inhibitors of poly(ADP)-ribose polymerase (PARP) exploit defective DNA repair pathways existing in several forms of cancer, such as those with BRCA mutations, and have proven clinical efficacy as chemosensitizers. However, platinum-based chemopotentiation by PARP inhibitors (PARPi), particularly for...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolzenburg, Lindsay R., Ainsworth, Barrett, Riley-Gillis, Bridget, Pakozdi, Tibor, Ammar, Areej, Ellis, Paul A., Wilsbacher, Julie L., Ramathal, Cyril Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729805/
https://www.ncbi.nlm.nih.gov/pubmed/35018214
http://dx.doi.org/10.18632/oncotarget.28162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729805/
https://www.ncbi.nlm.nih.gov/pubmed/35018214
http://dx.doi.org/10.18632/oncotarget.28162

Ejemplares similares